0.3023
7.27%
-0.0237
After Hours:
.3192
0.0169
+5.59%
China Pharma Holdings Inc. stock is currently priced at $0.3023, with a 24-hour trading volume of 232.71K.
It has seen a -7.27% decreased in the last 24 hours and a -14.96% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3194 pivot point. If it approaches the $0.28 support level, significant changes may occur.
Previous Close:
$0.326
Open:
$0.3085
24h Volume:
232.71K
Market Cap:
$4.48M
Revenue:
$7.78M
Net Income/Loss:
$-3.11M
P/E Ratio:
-0.6298
EPS:
-0.48
Net Cash Flow:
$-72,500
1W Performance:
-4.82%
1M Performance:
-14.96%
6M Performance:
+177.09%
1Y Performance:
-1.60%
China Pharma Holdings Inc. Stock (CPHI) Company Profile
Name
China Pharma Holdings Inc.
Sector
Phone
86 898 6681 1730
Address
No. 17, Jinpan Road, Second Floor, Haikou
China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-08-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
China Pharma Holdings Inc. Stock (CPHI) Latest News
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Nasdaq Surges Over 100 Points; US Economy Expands Faster Than Expected
Benzinga
China Pharma Holdings Inc. Stock (CPHI) Financials Data
China Pharma Holdings Inc. (CPHI) Revenue 2024
CPHI reported a revenue (TTM) of $7.78 million for the quarter ending September 30, 2023, a -3.59% decline year-over-year.
China Pharma Holdings Inc. (CPHI) Net Income 2024
CPHI net income (TTM) was -$3.11 million for the quarter ending September 30, 2023, a +15.68% increase year-over-year.
China Pharma Holdings Inc. (CPHI) Cash Flow 2024
CPHI recorded a free cash flow (TTM) of -$72.50 thousand for the quarter ending September 30, 2023, a +95.55% increase year-over-year.
China Pharma Holdings Inc. (CPHI) Earnings per Share 2024
CPHI earnings per share (TTM) was -$1.90 for the quarter ending September 30, 2023, a +52.50% growth year-over-year.
About China Pharma Holdings Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
Cap:
|
Volume (24h):